Chandra Bhagat PharmaShare price, financial results, shareholding and management

BSE SME · CBPLPharmaceuticals & Biotechnology
cbcpharma.com ↗Live price on BSE ↗ISIN INE07QQ01016 · Lot 1,000 shares · ₹65,990
₹65.99
-5.00% on the day
Close · 19 Nov 2026
Valuation
Market cap
₹50 cr
Stock P/E
16.3peers 19.8
Book value
₹45.1
Price to book
1.46
EV / operating profit
-
Market cap to sales
0.43
Returns and growth
ROCE · FY26
12.0%
ROE · FY26
9.5%
ROE, 3-year average
5.9%
Operating margin · FY26
3.3%peers 16.5%
Sales growth, 3 years
-1.0%
Profit growth, 3 years
49.7%
Safety
Debt to equity
0.50peers 0.35
Borrowings
₹17 cr
Interest cover
3.1×
Cash from business / op. profit
234%
Debtor days
171
Pledged
0.00%
Ownership and share
Promoter holding
73.02%
Change in promoter holding
+0.83 pts
Shareholders
280
52-week high / low
₹73 / ₹30
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.

Chandra Bhagat Pharma share price chart

₹65.99+65.18% 1 year

Close on 19 Nov 2026 · -4.98% on the day · Vol 18,000

Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 19 Nov 2026

1 month
+65.0%
3 months
+32.2%
6 months
+81.8%
1 year
+65.2%
Traded a day, 20 days
₹0.03 cr

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+34%+255%
3 years, a year-1%+50%
Latest half, H2 FY26+316%+1429%

Chandra Bhagat Pharma revenue and profit growth

Half-yearly results · Profit and loss

Sales have fallen. Last year profit grew faster than sales, so the company kept more from each rupee of sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
0100200300Sales, FY15: 61 ₹ cr61Net profit, FY15: 0 ₹ cr0FY15Sales, FY16: 80 ₹ cr80Net profit, FY16: 0 ₹ cr0FY16Sales, FY17: 90 ₹ cr90Net profit, FY17: 1 ₹ cr1FY17Sales, FY18: 97 ₹ cr97Net profit, FY18: 1 ₹ cr1FY18Sales, FY19: 106 ₹ cr106Net profit, FY19: 1 ₹ cr1FY19Sales, FY20: 94 ₹ cr94Net profit, FY20: 0 ₹ cr0FY20Sales, FY21: 71 ₹ cr71Net profit, FY21: 0 ₹ cr0FY21Sales, FY22: 94 ₹ cr94Net profit, FY22: 1 ₹ cr1FY22Sales, FY23: 120 ₹ cr120Net profit, FY23: 0.9 ₹ cr0.9FY23Sales, FY24: 221 ₹ cr221Net profit, FY24: 1.5 ₹ cr1.5FY24Sales, FY25: 86.7 ₹ cr86.7Net profit, FY25: 0.9 ₹ cr0.9FY25Sales, FY26: 116 ₹ cr116Net profit, FY26: 3.1 ₹ cr3.1FY26
The latest halves, ₹ crore
SalesNet profit
050100150Sales, H1FY23: 44.3 ₹ cr44.3Net profit, H1FY23: 0.4 ₹ cr0.4H1FY23Sales, H2FY23: 75.4 ₹ cr75.4Net profit, H2FY23: 0.5 ₹ cr0.5H2FY23Sales, H1FY24: 119 ₹ cr119Net profit, H1FY24: 0.6 ₹ cr0.6H1FY24Sales, H2FY24: 102 ₹ cr102Net profit, H2FY24: 0.9 ₹ cr0.9H2FY24Sales, H1FY25: 64.9 ₹ cr64.9Net profit, H1FY25: 0.7 ₹ cr0.7H1FY25Sales, H2FY25: 21.8 ₹ cr21.8Net profit, H2FY25: 0.2 ₹ cr0.2H2FY25Sales, H1FY26: 25.6 ₹ cr25.6Net profit, H1FY26: 0.2 ₹ cr0.2H1FY26Sales, H2FY26: 90.7 ₹ cr90.7Net profit, H2FY26: 2.6 ₹ cr2.6H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.

Chandra Bhagat Pharma half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H1FY23H2FY23H1FY24H2FY24H1FY25H2FY25H1FY26H2FY26
Sales44.2775.40119.26102.1164.9221.8025.5590.73
Expenses43.2573.60124.26104.1566.1222.0624.1888.54
Operating profit1.031.80-5-2.04-1.20-0.261.372.19
OPM2.3%2.4%-4.2%-2.0%-1.9%-1.2%5.4%2.4%
Interest1.041.150.660.730.851.100.811.19
Depreciation0.050.220.430.210.410.540.610.49
Profit before tax0.540.620.921.340.610.550.293.52
Net profit0.370.540.640.900.690.170.232.60

Chandra Bhagat Pharma profit and loss

Full years to March, FY15 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Sales61809097106947194119.67221.3786.72116.27
Expenses58768592102916791116.35228.4188.17112.42
Operating profit334553433.32-7.04-1.463.85
OPM4.9%4.3%4.9%4.7%4.3%3.3%5.0%3.0%2.8%-3.2%-1.7%3.3%
Other income000100020.2911.335.523.35
Interest234443432.191.391.952
Depreciation000000000.270.640.951.10
Exceptional and other items·11····-1····
Profit before tax111210011.162.261.174.11
Tax rate100.0%100.0%0.0%50.0%0.0%26.0%32.0%0.0%21.6%32.3%26.5%25.8%
Net profit001110010.911.530.863.05
EPS ₹10.298.3715.7924.6410.290.410.251.061.202.031.144.04
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

The years to FY22 come rounded to the nearest crore in the source.

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

A tax rate above 60% or below zero (FY15, FY16) comes from tax charged on a small or negative profit, as reported.

Earnings per share before FY20 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.

Chandra Bhagat Pharma profitability

Margins and returns on capital

Last year the company kept more from each rupee of sales than the year before. It earns a moderate return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

-5%-3%0%3%5%8%FY15: 4.9%4.9%FY15FY16: 4.3%4.3%FY16FY17: 4.9%4.9%FY17FY18: 4.7%4.7%FY18FY19: 4.3%4.3%FY19FY20: 3.3%3.3%FY20FY21: 5.0%5.0%FY21FY22: 3.0%3.0%FY22FY23: 2.8%2.8%FY23FY24: -3.2%-3.2%FY24FY25: -1.7%-1.7%FY25FY26: 3.3%3.3%FY26
Per cent
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Operating margin4.9%4.3%4.9%4.7%4.3%3.3%5.0%3.0%2.8%-3.2%-1.7%3.3%
Tax rate100.0%100.0%0.0%50.0%0.0%26.0%32.0%0.0%21.6%32.3%26.5%25.8%
ROCE·11.6%15.7%20.1%13.1%5.9%7.3%7.9%7.1%7.9%6.5%12.0%
ROE·0.0%14.5%12.6%8.7%0.0%0.0%3.8%3.3%5.4%2.9%9.5%
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Chandra Bhagat Pharma debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown. Its loans are smaller than its own money. Last year the business brought in more cash than it showed as profit. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
010203040Net worth, FY15: 6.4 ₹ cr6.4Borrowings, FY15: 28 ₹ cr28FY15Net worth, FY16: 6.4 ₹ cr6.4Borrowings, FY16: 28 ₹ cr28FY16Net worth, FY17: 7.4 ₹ cr7.4Borrowings, FY17: 22 ₹ cr22FY17Net worth, FY18: 8.4 ₹ cr8.4Borrowings, FY18: 22 ₹ cr22FY18Net worth, FY19: 14.7 ₹ cr14.7Borrowings, FY19: 31 ₹ cr31FY19Net worth, FY20: 26 ₹ cr26Borrowings, FY20: 30 ₹ cr30FY20Net worth, FY21: 26 ₹ cr26Borrowings, FY21: 27 ₹ cr27FY21Net worth, FY22: 27 ₹ cr27Borrowings, FY22: 21 ₹ cr21FY22Net worth, FY23: 28 ₹ cr28Borrowings, FY23: 19 ₹ cr19FY23Net worth, FY24: 29 ₹ cr29Borrowings, FY24: 16 ₹ cr16FY24Net worth, FY25: 30 ₹ cr30Borrowings, FY25: 21 ₹ cr21FY25Net worth, FY26: 34 ₹ cr34Borrowings, FY26: 17 ₹ cr17FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-1001020Cash from the business, FY15: 0 ₹ cr0Net profit, FY15: 0 ₹ cr0FY15Cash from the business, FY16: 0 ₹ cr0Net profit, FY16: 0 ₹ cr0FY16Cash from the business, FY17: -9 ₹ cr-9Net profit, FY17: 1 ₹ cr1FY17Cash from the business, FY18: -6 ₹ cr-6Net profit, FY18: 1 ₹ cr1FY18Cash from the business, FY19: 4 ₹ cr4Net profit, FY19: 1 ₹ cr1FY19Cash from the business, FY20: -7 ₹ cr-7Net profit, FY20: 0 ₹ cr0FY20Cash from the business, FY21: 8 ₹ cr8Net profit, FY21: 0 ₹ cr0FY21Cash from the business, FY22: 12 ₹ cr12Net profit, FY22: 1 ₹ cr1FY22Cash from the business, FY23: 5 ₹ cr5Net profit, FY23: 0.9 ₹ cr0.9FY23Cash from the business, FY24: 6 ₹ cr6Net profit, FY24: 1.5 ₹ cr1.5FY24Cash from the business, FY25: -6 ₹ cr-6Net profit, FY25: 0.9 ₹ cr0.9FY25Cash from the business, FY26: 9 ₹ cr9Net profit, FY26: 3.1 ₹ cr3.1FY26

Bars below the line are cash going out.

Chandra Bhagat Pharma balance sheet

At each 31 March · ₹ crore

₹ crore
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Equity capital0.420.420.420.420.678888888
Reserves66781418181920212226
Net worth6.426.427.428.4214.6726262728293034
Borrowings282822223130272119162117
Other liabilities7.589.5826.5827.5837.3319192414575143
Total liabilities42445658837572726110210294
Fixed assets111100001333
Capital work in progress000000000000
Investments005141000002
Other assets414350567974727260999989

Chandra Bhagat Pharma cash flow

₹ crore

₹ crore
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Cash from operations00-9-64-781256-69
Cash from investing000000000-2-10
Cash from financing0087-47-6-10-4-62-6
Net cash flow00-1100221-2-53

Working capital

Days

Days
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Debtor days71668067905480582565148171
Inventory days17712313314517418721515310015318
Days payable43338169117537912112345124
Cash conversion cycle2051561321431461882161991145710765
Working capital days16613412513883148177104753610177

Chandra Bhagat Pharma peers and competitors

Listed SME companies in the same industry

By sales, Chandra Bhagat Pharma is number 12 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Astonea Labs34168.114859.0%0.74
Influx Healthtech63230.814720.520.3%0.00
Jfl Life Sciences355.51316.48.9%0.47
Dipna Pharmachem113.512933.9%0.21
Trident Lifeline48125.31291922.0%0.73
Chandra Bhagat Pharma5016.31163.13.3%0.50
Quest Laboratories15410.31121516.3%0.08
KRM Ayurveda57328.61022030.0%0.00
Sotac Pharmaceuticals10017.31015.817.7%0.64
Accretion Pharmaceuticals21522.289.69.716.7%0.23
Walpar Nutritions259.978.82.58.5%0.89
Median of the 10 others18519.8120816.5%0.35

Chandra Bhagat Pharma shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company, a little more than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders has grown a lot.

Promoters
73.02%
+3.93 pts since Sep 22
Foreign investors (FIIs)
0.61%
at Sep 25; not in the latest pattern
Indian institutions (DIIs)
0.00%
at Sep 25; not in the latest pattern
Number of shareholders
280
126 in Sep 22

Chandra Bhagat Pharma shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Sep 22Mar 23Sep 23Mar 24Sep 24Mar 25Sep 25Mar 26
Promoters69.09%68.24%68.69%68.77%69.29%71.20%72.19%73.02%
Foreign investors (FIIs)0.85%0.85%1.33%1.33%0.48%0.61%0.61%-
Indian institutions (DIIs)0.00%0.00%0.89%0.89%0.00%0.00%0.00%-
Number of shareholders126146134152315316301280

Chandra Bhagat Pharma latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹90.7 cr (+316%), net profit ₹2.6 cr (+1429%) on H2 FY25.
  • Shareholding, 31 March 2026: promoters 72.19% to 73.02%.

Chandra Bhagat Pharma annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Chandra Bhagat Pharma share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Chandra Bhagat Pharma's data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • iThe shares traded on only 105 days in the past year, so the price, its range and the returns here rest on few trades.
  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (75,45,056 shares).
  • !The FY26 results imply 80,00,000 shares at face value ₹10, which disagrees with the shareholding pattern; the pattern is used.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • !Earnings per share changes basis between FY19 (₹10.29) and FY22 (₹1.06) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
  • ✓Revenue and profit are reported for every year shown, FY15 to FY26.
  • iPrices run to the close on 13 Oct 2026, from the exchange's daily figures.

Questions people ask about Chandra Bhagat Pharma

What does Chandra Bhagat Pharma do?

Chandra Bhagat Pharma is an SME company listed on BSE SME, in pharmaceuticals & biotechnology.

What is the share price of Chandra Bhagat Pharma?

₹66 at the close on 19 Nov 2026, from the exchange's daily figures.

What is the market cap of Chandra Bhagat Pharma?

₹50 cr at the close on 19 Nov 2026, on 75,45,056 shares.

What is the P/E of Chandra Bhagat Pharma?

16.3 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).

What are Chandra Bhagat Pharma's revenue and profit?

Revenue ₹116 cr and profit after tax ₹3 cr in FY26.

Who are the promoters of Chandra Bhagat Pharma?

The promoter group; promoters held 73.02% at 31 March 2026.

What is Chandra Bhagat Pharma's website?

www.cbcpharma.com

More SME companies like Chandra Bhagat Pharma

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology →

Built from 3 exchange announcements, 8 shareholding patterns and 12 years of reported results. Every figure carries its source; where the documents are silent, the page says so.